<DOC>
	<DOCNO>NCT02718482</DOCNO>
	<brief_summary>Phase II randomize study comparison Gemcitabine plus Docetaxel Ifosfamide treatment patient relapse osteosarcoma</brief_summary>
	<brief_title>Phase II Trial Treatment Relapsed Osteosarcoma</brief_title>
	<detailed_description>Patients relapse osteosarcoma randomize receive Gemcitabine plus Docetaxel High Doses Ifosfamide ( continuous infusion ) every 3 week , 6 week</detailed_description>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>Diagnosis high grade osteosarcoma recurrence Resectable unresectable recurrence disease within 24 month initial diagnosis Pleuropulmonary recurrence 2 nodule within 24 month initial diagnosis Unresectable first relapse within 24 month initial diagnosis Resectable unresectable second recurrence high grade osteosarcoma Age diagnosis least 4years . Karnofsky performance status 60 % . Renal function hepatic In normal limit age . L eft ejection ventricular fraction 50 % . White blood cell 3000 million/liter platelet 100000 million/liter Birth potential female must agree contraception Signed write informed consent Contraindication use study drug Mental , social geographic condition fail ensure adequate adherence study Hepatitis human immunodeficiency virus active infection Pregnancy breastfeed Previous treatment Gemcitabine , Docetaxel Ifosfamide</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>